UBA52 and metabolic dysfunction-associated steatotic liver disease: Similarly, Eriodictyol exhibits the potential to ameliorate nonalcoholic fatty liver disease (NAFLD) by modulating autophagy mediated by ubiquitin A‐52 (UBA52) and upregulating the Nrf2/HO‐1 (heme oxygenase‐1) signaling pathway to attenuate oxidative stress (Cai et al., 2024).